World's largest producer of hyaluronic acid, supplying raw material and finished dermal-filler and skincare products for medical aesthetics and cosmetics.
World's largest producer of hyaluronic acid, supplying raw material and finished dermal-filler and skincare products for medical aesthetics and cosmetics.
Began as an ingredient supplier selling hyaluronic acid by weight to cosmetic, drug and food makers, and has moved up the chain into its own skincare brands and injectable fillers, which capture more value per gram but cost more in marketing. Ingredient sales still follow volume and price of a commodity-like material.
In one line: A raw-material supplier plus a skincare brand owner rolled into one.
Moat: narrow (scale, process know-how, brand). World-leading fermentation-based HA production scale plus a growing portfolio of consumer skincare brands.
Headquarters: Jinan, China · Employees: 3,698
Size Bloomage Biotechnology (688363.SS) is a China Materials company (Chemicals: Specialty) with a market value of $2.27B, the 1063rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥31.55 on 18 Nov 2026.
Performance Over six months the shares fell 21.0%, against -16.7% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue fell 21.5% over the last twelve months (peer median +10.8%); the operating margin is 4.6% (peer median 7.5%).
Valuation It trades at 52.0× forward earnings against a peer median of 16.1× (3rd most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +9 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.8 points below its cost of capital (8.2% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.63B | CN¥4.17B | CN¥5.31B | CN¥6.01B | CN¥6.28B |
| Revenue growth | — | -21% | -12% | -4% | — |
| Gross profit | CN¥2.58B | CN¥2.72B | CN¥3.77B | CN¥4.28B | CN¥4.75B |
| EBITDA | n/a | CN¥627M | CN¥554M | CN¥860M | CN¥1.18B |
| Net income | CN¥226M | CN¥292M | CN¥174M | CN¥593M | CN¥971M |
| Free cash flow | CN¥532M | CN¥312M | -CN¥124M | -CN¥317M | -CN¥28.6M |
| Capital expenditure | CN¥363M | CN¥326M | CN¥721M | CN¥1.03B | CN¥696M |
| Total debt | CN¥489M | CN¥353M | CN¥360M | CN¥215M | CN¥421M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Bloomage Biotechnology 688363.SS | $2.27B | -21% | -22% | 5% | 52.0× | 19.0% |
| IMEIK Technology Development 300896.SZ | $3.66B | -25% | -7% | 45% | 22.4× | 17.5% |
| Galderma GALD.SW | $51.9B | +18% | +16% | 19% | 45.7× | 18.0% |
| AbbVie ABBV | $506B | +35% | +11% | 36% | 18.1× | -0.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688363.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.9% | -7.2% | 9th lowest of 21 |
| 6-month return | -21.0% | -16.7% | 9th lowest of 21 |
| Distance from 52-week high | -40.1% | -39.7% | 11th highest of 21 |
| Revenue growth (TTM) | -21.5% | +10.8% | lowest of 21 |
| Operating margin | 4.6% | 7.5% | 6th lowest of 20 |
| Forward P/E | 52.0× | 16.1× | 3rd most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 19.0% | 10.8% | 3rd most demanding of 12 |
| Growth delivered (Del g) | +9.8% | +8.0% | 4th highest of 12 |
| Hurdle (Req g minus delivered) | +9.2 pp | +10.3 pp | 6th least demanding of 12 |
| ROIC minus cost of capital | -2.8 pp | -1.3 pp | 6th lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Bloomage Biotechnology 688363.SS | China | $2.27B | -21% | -22% | 5% | 52.0× | 19.0% | +9.8% |
| Deepak Nitrite DEEPAKNTR.NS | India | $2.28B | -13% | +25% | 14% | 16.8× | n/a | n/a |
| Shanghai Huayi 600623.SS | China | $2.31B | -16% | +5% | n/a | 13.6× | -11.3% | +10.3% |
| Sichuan Qiaoyuan Gas 301286.SZ | China | $2.33B | -37% | +8% | 26% | 59.2× | 27.6% | +8.0% |
| Shandong Dongyue Silicone Material 300821.SZ | China | $2.19B | -23% | +13% | 13% | n/a | 18.8% | +8.6% |
| Kaneka 4118.T | Japan | $2.35B | +17% | +6% | 5% | 12.0× | 3.3% | +7.0% |
| Rogers ROG | United States | $2.18B | -8% | +7% | 10% | 26.3× | 10.8% | +0.2% |
| SKC 011790.KS | South Korea | $2.42B | -52% | +24% | -9% | n/a | n/a | n/a |
| Zhejiang Yonghe Refrigerant 605020.SS | China | $2.12B | -13% | +25% | 18% | 13.2× | n/a | n/a |
| Daicel 4202.T | Japan | $2.45B | +31% | +7% | 8% | 10.9× | 4.2% | +8.1% |
| China Petroleum Engineering 600339.SS | China | $2.46B | -22% | +8% | 1% | 24.5× | n/a | n/a |
| Kemira KEMIRA.HE | Finland | $2.47B | -12% | -3% | 8% | 15.8× | 3.9% | +2.6% |
| Sinochem International 600500.SS | China | $2.06B | -31% | -5% | -1% | n/a | 11.0% | -2.7% |
| Tinergy Chemical 002145.SZ | China | $2.06B | -20% | +17% | 9% | n/a | n/a | n/a |
| K+s SDF.DE | Germany | $2.51B | -13% | +7% | 28% | 10.5× | n/a | n/a |
| Qingdao Gon Technology 2768.HK | Hong Kong | $2.52B | -17% | +20% | 7% | 9.7× | n/a | n/a |
| Beijing Easpring Material Technology 300073.SZ | China | $2.56B | -45% | +116% | 5% | 17.8× | n/a | n/a |
| Shaanxi Beiyuan Chemical Industry 601568.SS | China | $1.99B | -13% | -8% | -4% | 11.1× | 10.5% | -1.8% |
| XTC New Energy Materials (Xiamen) 688778.SS | China | $2.59B | -51% | +78% | 4% | 16.5× | 13.7% | +20.0% |
| Epoxy Base Electronic Material 603002.SS | China | $1.98B | -22% | +73% | 7% | 64.6× | n/a | n/a |
| Garware Hi-Tech Films GRWRHITECH.NS | India | $1.95B | +42% | +15% | 21% | 38.7× | 39.5% | +16.6% |